Bimodal expression of

AML RHOH differentiation therapy myeloid differentiation

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
May 2021
Historique:
received: 29 05 2020
revised: 09 10 2020
accepted: 26 10 2020
entrez: 18 7 2022
pubmed: 20 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

RhoH is an unusual member of the Rho family of small GTP-binding proteins in that it lacks GTPase activity. Since the RhoH protein is constantly bound by GTP, it is constitutively active and controlled predominantly by changes in quantitative expression. Abnormal levels of

Identifiants

pubmed: 35845268
doi: 10.1002/jha2.128
pii: JHA2128
pmc: PMC9175762
doi:

Types de publication

Journal Article

Langues

eng

Pagination

196-210

Informations de copyright

© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Carl S. Shelley is President and CEO of Leukemia Therapeutics, LLC that is developing novel treatments for AML based on targeting the molecular consequences of aberrant RHOH repression.

Références

Leukemia. 2005 Mar;19(3):402-9
pubmed: 15674361
Blood. 2008 Nov 15;112(10):4193-201
pubmed: 18716133
Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24
pubmed: 26507857
Nucleic Acids Res. 2003 Jul 1;31(13):3651-3
pubmed: 12824386
Eur J Immunol. 2010 Feb;40(2):525-9
pubmed: 19950172
Leuk Res. 2009 May;33(5):649-54
pubmed: 19019431
Cancer Res. 2008 Jun 15;68(12):4531-40
pubmed: 18559497
Blood. 2017 Sep 14;130(11):1336-1346
pubmed: 28778865
Cell Death Differ. 2016 Dec;23(12):1961-1972
pubmed: 27740624
Oncogene. 2000 Apr 13;19(16):2023-32
pubmed: 10803463
Blood. 2006 Aug 1;108(3):1013-20
pubmed: 16614247
Exp Mol Med. 2018 Apr 20;50(4):1-8
pubmed: 29674693
Cell Signal. 2010 Jul;22(7):1022-32
pubmed: 20184954
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Nucleic Acids Res. 2019 Jan 8;47(D1):D881-D885
pubmed: 30395307
Oncogene. 1995 Jun 1;10(11):2171-8
pubmed: 7784061
Cancer Res. 1982 Apr;42(4):1530-6
pubmed: 6949641
Eur J Haematol. 2008 Dec;81(6):454-60
pubmed: 18691253
Blood. 2007 Apr 15;109(8):3500-4
pubmed: 17197434
Blood. 2007 Mar 15;109(6):2346-55
pubmed: 17119112
Exp Cell Res. 2013 Sep 10;319(15):2375-83
pubmed: 23850828
Blood. 2008 Mar 1;111(5):2597-605
pubmed: 18089848
PLoS One. 2009 Oct 16;4(10):e7475
pubmed: 19834619
Nat Immunol. 2004 Sep;5(9):961-7
pubmed: 15300248
Cells. 2019 Nov 07;8(11):
pubmed: 31703382
Nature. 2001 Jul 19;412(6844):341-6
pubmed: 11460166
PLoS One. 2008 May 14;3(5):e2141
pubmed: 18478077
Cell Cycle. 2005 Feb;4(2):201-2
pubmed: 15611634
Genes Chromosomes Cancer. 2008 Jan;47(1):8-20
pubmed: 17910043
Bioinformatics. 2002 Feb;18(2):333-4
pubmed: 11847087
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
J Invest Dermatol. 2009 Feb;129(2):476-9
pubmed: 18704108
Cancer Genet Cytogenet. 2006 Oct 1;170(1):78-9
pubmed: 16965962
Nat Commun. 2017 Jun 29;8(1):46
pubmed: 28663557
Small GTPases. 2018 May 4;9(3):260-273
pubmed: 27574848
Cancer Res. 2015 Sep 15;75(18):3902-11
pubmed: 26170397
Haematologica. 2006 Oct;91(10):1405-9
pubmed: 17018394
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Blood. 2012 May 17;119(20):4708-18
pubmed: 22474251
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
Blood. 2003 Sep 1;102(5):1833-41
pubmed: 12714522
Leukemia. 2007 Aug;21(8):1846-7
pubmed: 17443219
PLoS One. 2018 Jan 29;13(1):e0190447
pubmed: 29377892
J Immunol. 2009 Jan 15;182(2):957-62
pubmed: 19124738
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell Signal. 2011 Jan;23(1):249-58
pubmed: 20851766
Blood. 2005 Feb 15;105(4):1467-75
pubmed: 15494435
Br J Haematol. 2005 Sep;130(6):890-901
pubmed: 16156859
Biomed Pharmacother. 2018 Jan;97:1189-1194
pubmed: 29136958
Leuk Lymphoma. 2010 Sep;51(9):1711-9
pubmed: 20795789
Int J Mol Sci. 2019 Jul 24;20(15):
pubmed: 31344837
Immunol Lett. 2013 Mar;151(1-2):1-9
pubmed: 23499578
Br J Haematol. 2005 May;129(3):373-6
pubmed: 15842661
Nat Immunol. 2006 Nov;7(11):1182-90
pubmed: 17028588
Leukemia. 2010 Jan;24(1):97-104
pubmed: 19847197
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10474-9
pubmed: 22689994
J Immunol. 2009 May 15;182(10):6527-32
pubmed: 19414807
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Blood. 2006 Jun 15;107(12):4926-9
pubmed: 16507780
Nat Rev Cancer. 2018 Feb;18(2):117-127
pubmed: 29192213
Mol Biol Res Commun. 2018 Mar;7(1):25-33
pubmed: 29911120
Nature. 2016 Dec 15;540(7633):433-437
pubmed: 27926740
Mol Cancer. 2010 Aug 25;9:225
pubmed: 20738848
J Cell Physiol. 2015 Aug;230(8):1770-80
pubmed: 25502508
Blood. 2003 Feb 1;101(3):894-902
pubmed: 12393719
Biochem J. 2011 Jul 1;437(1):75-88
pubmed: 21473742
PLoS One. 2010 Nov 12;5(11):e13970
pubmed: 21103055
BMC Biol. 2018 Mar 6;16(1):29
pubmed: 29510700
Leukemia. 2007 Aug;21(8):1821-4
pubmed: 17476282
Zhonghua Zhong Liu Za Zhi. 2019 Oct 23;41(10):753-759
pubmed: 31648497
Oncotarget. 2017 Sep 15;8(50):87494-87511
pubmed: 29152097
Mol Cell Biol. 2002 Feb;22(4):1158-71
pubmed: 11809807

Auteurs

Sylvie Galiègue-Zouitina (S)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.

Qiangwei Fu (Q)

California Institute for Biomedical Research La Jolla California USA.

Céline Carton-Latreche (C)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.

Nicolas Poret (N)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.

Meyling Cheok (M)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.
Canther UMR 1277 Inserm-9020 CNRS Lille University Lille France.

Frédéric Leprêtre (F)

UMS 2014 - US 41 Plateau de Génomique Fonctionnelle et Structurale Lille University Lille France.

Martin Figeac (M)

UMS 2014 - US 41 Plateau de Génomique Fonctionnelle et Structurale Lille University Lille France.

Bruno Quesnel (B)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.
Canther UMR 1277 Inserm-9020 CNRS Lille University Lille France.
CHU Lille Service des Maladies du Sang Lille France.

Hassiba El Bouazzati (H)

JPARC UMRS 1172 Inserm Lille University Lille France.
Place de Verdun Institut pour la Recherche sur le Cancer de Lille Lille Cedex France.
Canther UMR 1277 Inserm-9020 CNRS Lille University Lille France.

Carl S Shelley (CS)

LLC Leukaemia Therapeutics Hull Massachusetts USA.

Classifications MeSH